leadf
logo-loader
viewZelira Therapeutics Ltd

Zelda Therapeutics advancing Australia-first insomnia trial

The company is well-placed to rapidly move into the commercialisation phase if required.

medicinal cannabis leaf with green tablets
Results are expected in late 2018

Zelda Therapeutics Ltd (ASX:ZLD) has completed patient recruitment for Australia’s first clinical study of medical cannabis to treat insomnia.

The next phase of the study will commence shortly with patients undergoing baseline sleep measurements before commencing pharmaceutical dosing.

Positive results will mean Zelda will rapidly focus on commercialisation

Zelda’s executive chairman Harry Karelis said: “This is a significant achievement for Zelda and has the potential to introduce a safe, effective and affordable treatment for patients.

“It is no small feat to be progressing a pioneering study of this nature using medicinal cannabis and is a testament to the quality of people involved that we have reached this point in such a rapid time-frame.

“Positive results will mean Zelda will rapidly focus on commercialisation activities in markets where we have existing knowledge, relationships and access to patients.”

READ: Zelda Therapeutics expands research program to include diabetes related cognitive decline

Zelda’s clinical trial will target a sample population of people with characteristic symptoms of chronic insomnia, which include difficulty falling and staying asleep on a long-term basis.

A randomised, placebo-controlled, cross over study design will be used, where patients are selected at random to be treated with Zelda’s medicinal cannabis formulation or a placebo formulation.

The study will be undertaken by the prestigious University of Western Australia (UWA) Centre for Sleep Science (CSS).

Results expected in late 2018

The study will collect and analyse data to determine the effect of the Zelda formulation on the time of onset of sleep, sleep cycle duration and quality of sleep.

In addition, subjective feedback from patients via standard questionnaires will be collected and analysed alongside the analytical data collected.

It is anticipated that preliminary results from this clinical trial will be available in late 2018.

Quick facts: Zelira Therapeutics Ltd

Price: 0.081 AUD

ASX:ZLD
Market: ASX
Market Cap: $96.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

3 weeks ago

2 min read